Initially, the combined company will be focused on the development of Diffusion's lead molecule trans sodium crocetinate
Diffusion Pharmaceuticals, a company developing new drugs to help regulate the movement of oxygen into tissue by a novel mechanism of action, has completed the enrolment of 56 patients with newly diagnosed primary brain cancer (glioblastoma multiforme) in the Phase II trial of an anti-cancer compound, trans sodium crocetinate
The company's first Phase I clinical trial for its lead molecule, trans sodium crocetinate
, shows the drug is well-tolerated in healthy human subjects at doses significantly higher than the estimated efficacious human dose.
Intravenous sodium crocetinate
does not alter gut hypercapnic responses or renal energy stores during transient ischemia.
Proceeds will be used by the company to support its ongoing operations, including the completion of a Phase I/II clinical trial in peripheral arterial disease (PAD) patients for its lead drug compound, trans sodium crocetinate